Created projects

Live projects

No projects found.

Draft projects

No projects found.

Pending Projects

No projects found.

Membership Projects

No projects found.

Suspended Projects

No projects found.

Expired Projects

    No projects found.

view all

You are logged in as Log out

Avanzarx: Pulmonary Fibrosis

by Robert Discordia

Stopping IPF in its Tracks
Rockville, MD United States Biotech Drug Development AI in Medicine

All Team Company Patients Innovation Details Supporters Comments Updates

About our project

The problem we solve: We are working to solve one of the most difficult challenges in modern medicine – developing an effective therapy for pulmonary fibrosis (https://my.clevelandclinic.org/health/diseases/10959-pulmonary-fibrosis). We are specifically targeting its most challenging forms, Idiopathic Pulmonary Fibrosis (IPF) and Scleroderma Lung Disease. These diseases significantly reduce patients’ quality of life and lifespan, but current therapies for these maladies are only marginally effective and have significant side-effects. We are developing a new drug, AVZ-1001, which we expect to be significantly more effective and have fewer side effects than the existing medicines. We have already accumulated a significant amount of data that drove us to believe in the therapeutic potential of AVZ-1001. We are seeking support to achieve our next goal, to bring AVZ-1001 into human clinical trials.

About our solution: We have identified a biologic target (an enzyme) that acts as a ‘regulatory hub’ controlling numerous pathways and cell types involved in lung fibrosis. We have exciting pre-clinical data showing that blocking this enzyme completely arrests the fibrotic process in the lungs of mice with induced lung fibrosis. We also have shown in preclinical animal testing that the drug has a very favorable safety profile. We want to rapidly advance AVZ-1001 to human testing.

Progress to date:

The technology behind this program has been developed and advanced over the last decade. Our results are supported by many unaffiliated researchers.  As such, the biologic target is much better understood and we have identified a potential drug that, in mice, effectively blocks this enzyme, causing the arrest of fibrosis.  This drug candidate is being advanced in pre-clinical tests with the goal of filing an IND (Investigational New Drug) application approximately 12 months from funding. We will proceed into human clinical safety trials (Phase-I testing) directly following IND approval from FDA.  

About Our Team

Creator: Robert Discordia

Location: North Carolina

Education: Syracuse University & Scripps (La Jolla)

Bio: Passionate, Biotech & Pharma executive and entrepreneur with over 30 years experience. Currently building Avanzarx Pharmaceuticals; a Virtual Discovery Platform to Clinical-Stage startup biotech focused on discovering and developing therapeutic assets to modulate new and/or heretofore unreachable immune system targets for inflammatory and fibrotic diseases.

Title: CEO

Advanced Degree(s): Ph.D.

About Team Members

Sergei Atamas
Chief Scientific Officer, M.D. Ph.D.
Biography: Dr. Sergei Atamas brings more than 30 years of academia and industry experience. He was Head Discovery and Non-Clinical Development at Corbus Pharmaceuticals and was tenured Professor of Medicine at the University of Maryland School of Medicine and the VA Medical Center. He specifically focuses on therapeutic targets for inflammatory and fibrotic diseases of the lungs. He has published more than 100 scientific articles.
Title: Chief Scientific Officer
Advanced Degree(s): M.D. Ph.D.
LinkedIn: https://www.linkedin.com/in/sergei-atamas/

About Our Company

Avanzarx Pharmaceuticals

Location: 2275 Research Blvd.
Suite 500 #80
Rockville, MD 20850

Founded: 2021

Website: http://www.avanzarx.com

Twitter: @bobdiscordia

Product Stage: Prototype/MVP

Employees: 5-10

How We Help Patients

Avanzarx's drug candidate, if successful, will significantly change the outlook for patients diagnosed with Interstitial Lung Disease, including but not limited to the most prevalent and fatal form, IPF (ideopathic pulmonary fibrosis).  Currently there are only 2 approved medications for IPF and both are only marginally effective and both have significant side-effects that cause many patients to discontinue use.  In pre-clinical testing, AVZ-1001 has shown remarkably, complete arrest of the fibrotic process (scarring in the lungs).  This could be an absolute game-changer for recently diagnosed patients who are faced with a life-expectancy of between 2 and 5 years. 

Innovation Details

Intellectual Property Summary

PCT/US2020/041212 patent application filed July 8, 2020

  • Publication No. WO2021/007329; published January 14, 2021

Provisional patent application to be filed August 2021 for prodrug derivatives of AVZ-1001

Patent Link
https://patents.google.com/patent/WO2021007329A2/en?oq=WO2021%2f007329

Clinical Information

AVZ-1001 is a pre-clinical drug candidate and as such, no clinical results yet exist.    

Regulatory Status

We expect to file an Investigational New Drug Application (IND) after completing our pre-clinical testing.  We expect this to occur in Q3-Q4/2022.

How we will use the funds raised

All funds will go to supporting the advancement of AVZ-1001 through pre-clinical testing.

Thank You

We are highly successful professionals with decades of experience. We know drug development and I (Bob) have been deeply involved in the successful development and commercialization of numerous drugs over my 30-year career. And, Sergei, a 30-year tenured professor of medicine at the University of Maryland, Baltimore, has had his entire research career dedicated to the study of immunology and its role in such diseases as IPF.  He is a highly regarded expert in this field.  That means, this is way, way more than just an idea for us; we are passionately connected to this pursuit; we believe we have something truly revolutionary to bring forward to IPF patients who are desparate for a significant improvement in therapeutic options.  We will relentlessly pursue the development of this drug and we'll pour every ounce of skill and talent into bringing a highly effective treatment for patients with IPF.  There is little hope for IPF patients currently; patients will succumb  to the disease within 2 to 5 years. But we want to change that!  We believe we may have a solution that will significantly change the outlook for patients.  Please help us to advance this.  Thank you for your generous support!

Supporters

    There are not supporters yet.

Comments

Login to post your comment!
Click here to Login

Updates

    No updates found .

0

Interest
Score

0

Adoption
Score
  • 21 Days left

$ 100,000 goal


Robert Discordia
CEO
Syracuse University & Scripps (La Jolla)

Proflle
Contact Me


Rewards All contributions are tax-deductible.